Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17813049 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL19426268 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL14282838 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL23485849 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8531995 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL24398891 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8529263 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2361 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2362 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8625934 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015813-A1 | PACKING MATERIAL FOR LIQUID CHROMATOGRAPHY AND COLUMN FOR LIQUID CHROMATOGRAPHY | SHOWA DENKO K.K. (JP) | 2019-01-17 | — | — | US | claimed |
| EP-3112858-B1 | PACKING MATERIAL FOR LIQUID CHROMATOGRAPHY AND COLUMN FOR LIQUID CHROMATOGRAPHY | SHOWA DENKO KK (JP) | 2018-05-23 | — | — | EP | claimed |
| US-20170007981-A1 | PACKING MATERIAL FOR LIQUID CHROMATOGRAPHY AND COLUMN FOR LIQUID CHROMATOGRAPHY | SHOWA DENKO K.K. (JP) | 2017-01-12 | — | — | US | claimed |
| EP-3112858-A1 | FILLER FOR LIQUID CHROMATOGRAPHY AND LIQUID CHROMATOGRAPHY COLUMN | Showa Denko K.K. (JP) | 2017-01-04 | — | — | EP | claimed |
| EP-3346266-B1 | LIQUID CHROMATOGRAPHY COLUMN AND LIQUID CHROMATOGRAPHY DEVICE EQUIPPED WITH SAME | RESONAC CORP (JP) | 2023-07-19 | — | — | EP | disclosed |
| CN-108290849-B | Contrast agents | 伯拉考成像股份公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11021451-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-06-01 | — | — | US | disclosed |
| EP-3386953-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| CN-107923884-B | Column for liquid chromatography and liquid chromatography apparatus provided with same | 昭和电工株式会社 | 2020-10-16 | — | — | CN | disclosed |
| US-20200325108-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-10781188-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-09-22 | — | — | US | disclosed |
| US-20190015813-A1 | PACKING MATERIAL FOR LIQUID CHROMATOGRAPHY AND COLUMN FOR LIQUID CHROMATOGRAPHY | SHOWA DENKO K.K. (JP) | 2019-01-17 | — | — | US | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-5844103-A | Anionic glycasuccinamide sufactants and a process for their manufacture | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| US-5786468-A | NONIONIC SURFACTANTS DERIVED FROM CARBOHYDRATES FOR SHAMPOO, DEODORANTS OR CLEANING COMPOUNDS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5631389-A | SUCCINAMIDES WITH SUGAR GROUPS, POLLUTION CONTROL, BIODEGRADABLE | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5541341-A | CARBOHYDRATE BASED SURFACTANTS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021451-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | LMNA 3726/4885L3MBTL1 3138/4885TDP1 3731/4885 |
| US-20200325108-A1 | CONTRAST AGENTS | SLC39A14, ABCB7, SLC40A1 | LMNA 3726/4885L3MBTL1 3138/4885TDP1 3731/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | LMNA 3066/4885L3MBTL1 1699/4885TDP1 751/4885 |
| US-10781188-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | LMNA 3726/4885L3MBTL1 3138/4885TDP1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.